The GnRH antagonist cetrorelix: established indications and future potential

References

• Schally AV, Comaru-Schally AM, Nagy A et al. Hypothalamic hormones and cancer. Front. Neuroendocrinol.22(4), 248–291 (2001).
   PubMed Web of Science ®Google Scholar
• Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides20(10), 1247–1262 (1999).
   PubMed Web of Science ®Google Scholar
• Schally AV, Arimura A, Baba Y et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem. Biophys. Res. Commun.43(2), 393–399 (1971).
   PubMed Web of Science ®Google Scholar
• Schally AV, Baba Y, Nair RM, Bennett CD. The amino acid sequence of a peptide with growth hormone-releasing activity isolated from porcine hypothalamus. J. Biol. Chem.246(21), 6647–6650 (1971).
   PubMed Web of Science ®Google Scholar
• Schally AV. LH-RH analogues: I. Their impact on reproductive medicine. Gynecol. Endocrinol.13(6), 401–409 (1999).
   PubMed Web of Science ®Google Scholar
• McArdle CA, Davidson JS, Willars GB. The tail of the gonadotrophin-releasing hormone receptor: desensitization at, and distal to, G protein-coupled receptors. Mol. Cell Endocrinol.151(1–2), 129–136 (1999).
   PubMed Web of Science ®Google Scholar
• Engel JB. New peptidic and non-peptidic GnRH antagonists. In: GnRH Analogs in Human Reproduction. Lunenfeld B (Ed.), Taylor & Francis, London, UK (2005).
   Google Scholar
• Bajusz S, Csernus VJ, Janaky T, Bokser L, Fekete M, Schally AV. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int. J. Pept. Protein Res.32(6), 425–435 (1988).
   PubMedGoogle Scholar
• Bokser L, Bajusz S, Groot K, Schally AV. Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75. Proc. Natl Acad. Sci. USA87(18), 7100–7104 (1990).
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Westphalen S, Hu W et al. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol. Oncol.90(3), 552–559 (2003).
   PubMed Web of Science ®Google Scholar
• Roulier R, Chabert-Orsini V, Sitri MC, Barry B, Terriou P. Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment. Reprod. Biomed. Online7(2), 185–189 (2003).
   PubMedGoogle Scholar
• Engel JB, Audebert A, Frydman R, Zivny J, Diedrich K. Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study. Eur. J. Obstet. Gynecol. Reprod. Biol. doi:10.1016/j.ejogrb.2006.07.018 (2006) (Epub ahead of print).
   PubMedGoogle Scholar
• Kupker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K. Use of GnRH antagonists in the treatment of endometriosis. Reprod. Biomed. Online5(1), 12–16 (2002).
   PubMedGoogle Scholar
• Cetrotide. Physician Desk Reference.
   Google Scholar
• Engel JB, Felberbaum RE, Eilers W, Polack S, Ortmann O, Diedrich K. Clomiphene-induced LH surges and cetrorelix. Reprod. Biomed. Online5(2), 109–111 (2002).
   PubMedGoogle Scholar
• Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F et al. Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate24(2), 84–92 (1994).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barcena D, Vadillo Buenfil M, Garcia Procel E et al. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, cetrorelix (SB-75). Eur. J. Endocrinol.131(3), 286–292 (1994).
   PubMed Web of Science ®Google Scholar
• Olivennes F, Fanchin R, Bouchard P et al. The single or dual administration of the gonadotropin-releasing hormone antagonist cetrorelix in an in vitro fertilization-embryo transfer program. Fertil. Steril.62(3), 468–476 (1994).
   PubMed Web of Science ®Google Scholar
• Diedrich K, Felberbaum R. New approaches to ovarian stimulation. Hum. Reprod.13(Suppl. 3), 1–13 (1998).
   PubMed Web of Science ®Google Scholar
• Felberbaum RE, Germer U, Ludwig M et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist cetrorelix. Hum. Reprod.13(6), 1660–1668 (1998).
   PubMed Web of Science ®Google Scholar
• Felberbaum RE, Albano C, Ludwig M et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum. Reprod.15(5), 1015–1020 (2000).
   PubMed Web of Science ®Google Scholar
• Reissmann T, Schally AV, Bouchard P, Riethmiiller H, Engel J. The LHRH antagonist cetrorelix: a review. Hum. Reprod. Update6(4), 322–331 (2000).
   PubMed Web of Science ®Google Scholar
• Emons G, Grundker C, Gunthert AR, Westphalen S, Kavanagh J, Verschraegen C. GnRH antagonists in the treatment of gynecological and breast cancers. Endocr. Relat. Cancer10(2), 291–299 (2003).
   PubMed Web of Science ®Google Scholar
• Behre HM, Bockers A, Schlingheider A, Nieschlag E. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men. Clin. Endocrinol. (Oxf.)40(2), 241–248 (1994).
   PubMedGoogle Scholar
• Klingmuller D, Schepke M, Enzweiler C, Bidlingmaier F. Hormonal responses to the new potent GnRH antagonist cetrorelix. Acta Endocrinol. (Copenh.)128(1), 15–18 (1993).
   PubMedGoogle Scholar
• Gonzalez-Barcena D, Vadillo-Buenfil M, Cortez-Morales A et al. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology45(2), 275–281 (1995).
   PubMed Web of Science ®Google Scholar
• Engel JB, Schally AV. Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat. Clin. Pract. Endocrinol. Metab.3(2), 157–167 (2007).
   PubMedGoogle Scholar
• Engel JB, Olivennes F, Fanchin R et al. Single dose application of cetrorelix in combination with clomiphene for friendly IVF: results of a feasibility study. Reprod. Biomed. Online6(4), 444–447 (2003).
   PubMedGoogle Scholar
• Engel JB, Ludwig M, Felberbaum R, Albano C, Devroey P, Diedrich K. Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to ‘friendly IVF’? Hum. Reprod.17(8), 2022–2026 (2002).
   PubMedGoogle Scholar
• Felberbaum R, Diedrich K. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists. Hum. Reprod.14(Suppl. 1), 207–221 (1999).
   PubMed Web of Science ®Google Scholar
• Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch. Gynecol. Obstet.265(4), 175–182 (2001).
   PubMedGoogle Scholar
• Ludwig M, Felberbaum RE, Devroey P et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch. Gynecol. Obstet.264(1), 29–32 (2000).
   PubMed Web of Science ®Google Scholar
• Albano C, Felberbaum RE, Smitz J et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum. Reprod.15(3), 526–531 (2000).
   PubMed Web of Science ®Google Scholar
• Olivennes F, Belaisch-Allart J, Emperaire JC et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil. Steril.73(2), 314–320 (2000).
   PubMed Web of Science ®Google Scholar
• Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum. Reprod.13(9), 2411–2414 (1998).
   PubMed Web of Science ®Google Scholar
• Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertil. Steril.67(5), 917–922 (1997).
   PubMed Web of Science ®Google Scholar
• Olivennes F, Diedrich K, Frydman R, Felberbaum RE, Howles CM. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod. Biomed. Online6(4), 432–438 (2003).
   PubMedGoogle Scholar
• Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst. Rev.3, CD001750 (2006).
   Google Scholar
• Hernandez ER. Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum. Reprod.15(6), 1211–1216 (2000).
   PubMed Web of Science ®Google Scholar
• Engel JB, Riethmuller-Winzen H, Diedrich K. Extrapituitary effects of GnRH antagonists in assisted reproduction: a review. Reprod. Biomed. Online10(2), 230–234 (2005).
   PubMedGoogle Scholar
• Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum. Reprod. Update12, 651–671 (2006).
   PubMed Web of Science ®Google Scholar
• Fasouliotis SJ, Laufer N, Sabbagh-Ehrlich S, Lewin A, Hurwitz A, Simon A. Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF. J. Assist. Reprod. Genet.20(11), 455–460 (2003).
   PubMed Web of Science ®Google Scholar
• Cheung LP, Lam PM, Lok IH et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum. Reprod.20(3), 616–621 (2005).
   PubMed Web of Science ®Google Scholar
• Bahceci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J. Reprod. Med.50(2), 84–90 (2005).
   PubMed Web of Science ®Google Scholar
• Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod. Biomed. Online13(5), 628–638 (2006).
   PubMed Web of Science ®Google Scholar
• Allegra A, Marino A, Coffaro F et al. GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Hum. Reprod.22(1), 101–108 (2007).
   PubMed Web of Science ®Google Scholar
• Pelinck MJ, Vogel NE, Hoek A, Arts EG, Simons AH, Heineman MJ. Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH: a pilot study. Hum. Reprod.20(3), 642–648 (2005).
   PubMed Web of Science ®Google Scholar
• Weghofer A, Margreiter M, Bassim S, Sevelda U, Beilhack E, Feichtinger W. Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age. Fertil. Steril.81(4), 1002–1006 (2004).
   PubMed Web of Science ®Google Scholar
• Diedrich RF, Audebert A, Zivny J, Engel JB. Presurgical short term treatent of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study. 8th International Symposion on GnRH Analogues in Cancer and Human Reproduction. Salzburg, Austria, February 10–13 (2005).
   Google Scholar
• Diedrich K, Frydman R, Devroey P et al. Comment on the debate article: embryo implantation: the Rubicon for GnRH antagonists. Hum. Reprod.16(6), 1305–1306 (2001).
   PubMedGoogle Scholar
• Donnez JOP, Barsukov A. Dose finding study of the LHRH antagonist cetrorelix, given over a period of 8 weeks, in the treatment of endometriosis. 8th International Symposion on GnRH Analogues in Cancer and Human Reproduction. Salzburg, Austria, February 10–13 (2005).
   Google Scholar
• Debruyne FMJ, Bantschev A, Tzvetkov M, Grdovic K. LHRH antagonist cetrorelix in the treatment of BPH: results from two randomized, placebo-controlled multicenter trials. 8th International Symposion on GnRH Analogues in Cancer and Human Reproduction. Salzburg, Austria, February 10–13 (2005).
   Google Scholar
• Lepor H. The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Rev. Urol.8(4), 183–189 (2006).
   PubMedGoogle Scholar
• Maudsley S, Davidson L, Pawson AJ et al. Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5. Neuroendocrinology84(5), 285–300 (2006).
   PubMedGoogle Scholar
• Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD, Schally AV. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J. Clin. Endocrinol. Metab.77(6), 1458–1464 (1993).
   PubMed Web of Science ®Google Scholar
• Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum. Reprod.9(7), 1364–1379 (1994).
   PubMed Web of Science ®Google Scholar
• Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J. Urol.163(2), 623–629 (2000).
   PubMed Web of Science ®Google Scholar
• Szepeshazi K, Halmos G, Schally AV et al. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. J. Cancer Res. Clin. Oncol.125(8–9), 444–452 (1999).
   PubMed Web of Science ®Google Scholar
• Halmos G, Schally AV, Kahan Z. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist cetrorelix. Int. J. Oncol.17(2), 367–373 (2000).
   PubMedGoogle Scholar
• Emons G, Ortmann O, Becker M et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res.53(22), 5439–5446 (1993).
   PubMed Web of Science ®Google Scholar
• Limonta P, Pratesi G, Moretti RM, Montagnani Marelli M, Motta M, Dondi D. Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II, Jungwirth et al., Eur. J. Cancer33(7), 1141–1148 (1997). Eur. J. Cancer34(7), 1134–1136 (1998).
   PubMedGoogle Scholar
• Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Cancer Medicine, 5th Edition. Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland RF, Frei E (Eds). Decker, NY, USA, 715–729 (2000).
   Google Scholar
• Wormald PJ, Eidne KA, Millar RP. Gonadotropin-releasing hormone receptors in human pituitary: ligand structural requirements, molecular size, and cationic effects. J. Clin. Endocrinol. Metab.61(6), 1190–1194 (1985).
   PubMedGoogle Scholar
• O’Byrne KJ, Dobbs N, Propper DJ et al. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br. J. Cancer79(9–10), 1413–1418 (1999).
   PubMed Web of Science ®Google Scholar
• Eidne KA, Flanagan CA, Harris NS, Millar RP. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J. Clin. Endocrinol. Metab.64(3), 425–432 (1987).
   PubMed Web of Science ®Google Scholar
• Emons G, Schulz KD. Primary and salvage therapy with LH-RH analogues in ovarian cancer. Recent Results Cancer Res.153, 83–94 (2000).
   PubMedGoogle Scholar
• Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br. J. Cancer62(1), 96–99 (1990).
   PubMedGoogle Scholar
• Pinski J, Yano T, Miller G, Schally AV. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75. Prostate20(3), 213–224 (1992).
   PubMedGoogle Scholar
• Sharoni Y, Bosin E, Miinster A, Levy J, Schally AV. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc. Natl Acad. Sci. USA86(5), 1648–1651 (1989).
   PubMedGoogle Scholar
• Engel JB, Diedrich K. Five years’ clinical use of GnRH antagonists: evaluation of safety and allergic potential. Reprod. Biomed. Online10(Suppl. 3), 61–65 (2005).
   PubMedGoogle Scholar